Gilead Sciences (GILD) and Immunomedics (IMMU) $21bn acquisition information including expected completion date, offer price and contact details are displayed in the acquisition details table below. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
This deal was successfully consummated on October 22, 2020
Immunomedics (IMMU) Acquisition
Receive FREE instant access to constantly updated IMMU news related to the current acquisition. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click Immunomedics (IMMU). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “IMMU“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders and shareholders can review similar acquisition details on current takeover stocks by first selecting “DEALS” from the main menu above, then “Current Cash Deals” or “Current Stock Deals“. For previous acquisitions, select either “Closed Deals” or “Failed Deals“. See our Spread Tracker News for mergers and acquisitions updates on the existing T20 Index portfolio constituents. Additionally, check out our customized M&A PR Newswire or Business Wire press release news feeds exclusively for Merger Arbitrage Limited.
Immunomedics (NASDAQ: IMMU) Acquisition - Merger News and Events
The major acquisition news updates & events of Immunomedics (IMMU) by Gilead Sciences (GILD) are listed below. A comprehensive data source for
- Traders looking to familiarize themselves with the Gilead Sciences (GILD) buyout of Immunomedics (IMMU) and trade the merger arbitrage spread
- Existing shareholders and investors wishing to stay abreast of the latest deal developments.
Following the acquisition news section, there is an in-depth company profile.
Immunomedics Company Profile
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States.
It also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company has clinical collaboration with AstraZeneca, MedImmune, and Roche; collaboration agreement with The Bayer Group; clinical and preclinical collaborations with academic cancer institutions; and research collaboration with the Memorial Sloan Kettering Cancer Center.
It also has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
